Bristol-Myers Squibb and AstraZeneca
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride ...